SOLUTION STRUCTURE OF HUMAN THIOREDOXIN IN A MIXED DISULFIDE INTERMEDIATE COMPLEX WITH ITS TARGET PEPTIDE FROM THE TRANSCRIPTION FACTOR NF-KAPPA-B

被引:207
作者
QIN, J [1 ]
CLORE, GM [1 ]
KENNEDY, WM [1 ]
HUTH, JR [1 ]
GRONENBORN, AM [1 ]
机构
[1] NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892
基金
美国国家卫生研究院;
关键词
DISULFIDE-BONDED INTERMEDIATE; HUMAN THIOREDOXIN; TRANSCRIPTION FACTOR NF-KAPPA-B;
D O I
10.1016/S0969-2126(01)00159-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Human thioredoxin is a 12 kDa cellular redox protein that plays a key role in maintaining the redox environment of the cell. It has recently been shown to be responsible for activating the DNA-binding properties of the cellular transcription factor, NF kappa B, by reducing a disulfide bond involving Cys62 of the p50 subunit. Using multidimensional heteronuclear-edited and heteronuclear-filtered NMR spectroscopy, we have solved the solution structure of a complex of human thioredoxin and a 13-residue peptide extending from residues 56-68 of p50, representing a kinetically stable mixed disulfide intermediate along the reaction pathway. Results: The NF kappa B peptide is located in a long boot-shaped cleft on the surface of human thioredoxin delineated by the active-site loop, helices alpha 2, alpha 3 and alpha 4, and strands beta 3 and beta 4. The peptide adopts a crescent-like conformation with a smooth 110 degrees bend centered around residue 60 which permits it to follow the path of the cleft. Conclusions: In addition to the intermolecular disulfide bridge between Cys32 of human thioredoxin and Cys62 of the peptide, the complex is stabilized by numerous hydrogen-bonding, electrostatic and hydrophobic interactions which involve residues 57-65 of the NF kappa B peptide and confer substrate specificity. These structural features permit one to suggest the specificity requirements for human thioredoxin-catalyzed disulfide bond reduction of proteins.
引用
收藏
页码:289 / 297
页数:9
相关论文
共 85 条
  • [1] REDOX REGULATION OF FOS AND JUN DNA-BINDING ACTIVITY INVITRO
    ABATE, C
    PATEL, L
    RAUSCHER, FJ
    CURRAN, T
    [J]. SCIENCE, 1990, 249 (4973) : 1157 - 1161
  • [2] BANNISTER AJ, 1991, ONCOGENE, V6, P1243
  • [3] BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63
  • [4] BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141
  • [5] METHODOLOGICAL ADVANCES IN PROTEIN NMR
    BAX, A
    GRZESIEK, S
    [J]. ACCOUNTS OF CHEMICAL RESEARCH, 1993, 26 (04) : 131 - 138
  • [6] ISOTOPE-FILTERED 2D HOHAHA SPECTROSCOPY OF A PEPTIDE-PROTEIN COMPLEX USING HETERONUCLEAR HARTMANN-HAHN DEPHASING
    BAX, A
    GRZESIEK, S
    GRONENBORN, AM
    CLORE, GM
    [J]. JOURNAL OF MAGNETIC RESONANCE SERIES A, 1994, 106 (02) : 269 - 273
  • [7] BAX A, 1994, METHOD ENZYMOL, V239, P79
  • [8] ENZYMATIC REDUCTION OF DISULFIDE BONDS IN FIBRIN-OGEN BY THIOREDOXIN SYSTEM .1. IDENTIFICATION OF REDUCED BONDS AND STUDIES ON REOXIDATION PROCESS
    BLOMBACK, B
    BLOMBACK, M
    FINKBEINER, W
    HOLMGREN, A
    KOWALSKA.B
    OLOVSON, G
    [J]. THROMBOSIS RESEARCH, 1974, 4 (01) : 55 - 75
  • [9] CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS
    BROOKS, BR
    BRUCCOLERI, RE
    OLAFSON, BD
    STATES, DJ
    SWAMINATHAN, S
    KARPLUS, M
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) : 187 - 217
  • [10] Brunger A. T., X PLOR VERSION 3 1 S